EviCore by Evernorth’s Post

This study compares TMVI and SMVR for intermediate-risk mitral valve disease patients, revealing TMVI's superiority in achieving higher 30-day device success rates (82.5% vs. 57.5%). Secondary outcomes like mortality, major bleeding, and complications were similar across both groups, suggesting TMVI's efficacy and safety. The findings suggest TMVI's consideration in clinical decision-making, highlighting its potential as a less invasive yet effective alternative to SMVR. https://ow.ly/A0lV50QOOm6 Johannes A. Ziegelmueller

Even though most patients with peripheral vascular disease have mild symptoms, many receive invasive treatment that is unnecessary and costly. An evidence-based approach to PVD treatment will lead to improved outcomes for patients while lowering the overall cost of treatment. Learn more in our latest white paper: https://bit.ly/3Vb4qXE

Register here: https://bit.ly/43NxaqD ADPKD is the most common hereditary kidney disease and the most common form of PKD. In this activity, expert faculty and an ADPKD patient present and discuss today’s current challenges in optimal patient care.

Referral patterns and co-management strategies of retinal disease are changing the way patients are being treated. When you factor in systemic conditions, like cardiac, cerebral, and renal diseases that may be detected in OCT scans, the playing field broadens. Are you offering your target audience the resources they need to leverage your solutions for patient care? Make a difference: https://lnkd.in/gW6-Mjmp

Below knee popliteal-distal bypass is a safe and effective approach to treat severe tibial vessel occlusive disease in this challenging patient cohort. Patients exhibited low peri-operative complication rates and good amputation-free survival at one year.

IVUS guided atherectomy with orbital atherectomy in a claudicant patient with long SFA disease. Significant less stent length with an IVUS guided bail-out strategy. Many thanks to Veryan Medical for supporting this live-case.

The overall rate of ipsilateral reintervention after CEA is low. A small percentage of patients will progress their contralateral disease, ultimately requiring surgical intervention. These data suggest regular duplex surveillance following CEA is warranted for patients with at least moderate contralateral disease, however, the yield is low for ipsilateral restenosis after 36 months based on this single institution study. Further study is needed to better delineate which patients need follow up to decrease unnecessary testing while still targeting patients most at risk of restenosis or contralateral progression of disease.

The J-point is elevated but < 2.0 mm, pattern recognition cannot be considered as CAD/AMI, correct? The patient is a 36-year-old male with obvious symptoms of coronary artery disease (CAD) confirmed by coronary angiography (CAG): Left anterior descending artery (LAD) stenosis 80%, right coronary artery (RCA) stenosis 70%, and left circumflex artery (LCx) stenosis 90%.

Have you seen our 2022 ACTION-VAD Registry data report? Key findings include: • Over 1,000 devices with over 200,000 device days in the database • Continued shift of patient diagnosis with now 37% of patients with congenital heart disease • Stroke incidence of 12% shows sustained improvement compared to historical reports It’s available on our website - https://bit.ly/46GtAAp! The report is cumulative and includes data from April 2018 – December 2022. #PedsVAD

Patients with severe claudication and CLI typically present extensive femoropopliteal occlusive disease. Although the use of new techniques and modern instruments makes it possible to treat an increasing number of patients with endovascular techniques, critical issues remain in the treatment of this specific vascular segment. Koen Deloose, Anahita Dua and Marta Lobato talked about the currently available methods to treat obstructive femoropopliteal lesions. #clicourses #CLTI #criticallimbischemia #vascular #endovascular